GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ananda Pharma PLC (AQSE:ANA) » Definitions » Notes Receivable

Ananda Pharma (AQSE:ANA) Notes Receivable : £0.00 Mil (As of Jul. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ananda Pharma Notes Receivable?

Ananda Pharma's Notes Receivable for the quarter that ended in Jul. 2024 was £0.00 Mil.


Ananda Pharma Notes Receivable Historical Data

The historical data trend for Ananda Pharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ananda Pharma Notes Receivable Chart

Ananda Pharma Annual Data
Trend Jan19 Jan20 Jan21 Jan22 Jan23
Notes Receivable
- - - - -

Ananda Pharma Semi-Annual Data
Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jul24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ananda Pharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Ananda Pharma Notes Receivable Related Terms

Thank you for viewing the detailed overview of Ananda Pharma's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Ananda Pharma Business Description

Traded in Other Exchanges
N/A
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Ananda Pharma PLC is focused on the development of cannabinoid therapies for the treatment of a range of complex conditions. The company is developing NHS-approved and MHRA-licensed cannabinoid medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with CIPN & endometriosis) and HFpEF heart failure.

Ananda Pharma Headlines

No Headlines